Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer.
Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer.
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.
Vidac Pharma Holdings plc has released the results of preclinical studies with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors.
Dren Bio Inc. has entered into a strategic collaboration with Novartis Pharma AG which will focus on the discovery and development of therapeutic bispecific antibodies for cancer leveraging Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
Pinetree Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc for a preclinical epidermal growth factor receptor (EGFR) degrader candidate.
Frontier Medicines Corp. has advanced lead candidates for further optimization in an Abbvie Inc.-partnered program targeting a key transcription factor for cancer cell survival, triggering an accompanying milestone payment.
Proteasome inhibitors such as bortezomib have shown promise in ovarian cancer treatment but limitations like route of administration or severe side effects restrict their use. Targeting proteasomal ubiquitin receptor ADRM1, also known as RPN13, has emerged as an alternative strategy and some RPN13 inhibitors are in early development.
RSS
